Eli Lilly | LLY - Selling And Administration Expenses


Eli Lilly reported $3.12B in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Abbott USD 4.27B 669M Sep/2026
ALKERMES USD 190.54M 6.1M Sep/2026
Amgen USD 1.68B 40M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Baxter International USD 730M 5M Sep/2026
Biogen USD 752M 42.3M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Drreddys Laboratories INR 28.08B 13.61B Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Glaxosmithkline GBP 2.38B 264M Sep/2026
J&J USD 6.25B 168M Sep/2026
Medtronic 3.2B 141M Jun/2026
Merck USD 2.86B 25M Sep/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Novartis USD 3.08B 58M Sep/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Perrigo USD 271.7M 3.01B Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 2.08B 2.04B Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
Sanofi EUR 2.63B 140M Jun/2026
United Therapeutics USD 184.1M 22.6M Sep/2026
Zoetis USD 582M 10M Sep/2026